NDD Medical Technologies (NDD), a global leader and innovator of diagnostic devices for the early detection of COPD and other chronic lung diseases, is pleased to announce the appointment of Michael Bencak as Chief Executive Officer. Michael has two decades of experience in the medical device and biotechnology industry, including most recently at BEKA Scientific GmbH and Zinsser Analytic GmbH as Chief Executive Officer, where he repeatedly produced sustained revenue and Earnings Before Interest and Taxes (EBIT) growth in dynamic and evolving markets. Michael joins NDD at an exciting time, with the company exhibiting rapid growth due to the increasing demand for spirometry and DLCO devices.
NDD was founded by Professor Karl Harnoncourt and Dr. Christian Buess, now Chief Technology Officer, after identifying an urgent need for advancements in pulmonary testing. With consistent growth throughout their 25-year history, NDD is the global leader in lung function testing and pulmonary function test devices, with innovative devices such as the EasyOne® product line providing much-needed point-of-care solutions. Committed to improving the lives of patients with the early detection and diagnosis of COPD and other chronic lung diseases, at a time of accelerating demand for additional lung testing due to long-Covid, NDD prides itself on the development of new and innovative solutions.
Former CEO and now Chief Strategy Officer, Georg Harnoncourt, said “NDD has provided innovative lung function testing devices since 1996, with the mission of helping physicians around the world to rapidly identify and diagnose respiratory disease. We are excited to welcome Michael to the NDD family. His exemplary leadership track record, a wealth of medical technology experience and proven ability to drive results, makes him the right leader to build on NDD’s heritage and steer our future development at this pivotal time of expanding innovation.”
Commenting on his new appointment as CEO, Michael Bencak says “I am delighted to join NDD. The business has a fantastic team and I feel honored to be able to build on the great foundations and innovative culture fostered by Georg and Christian. I am committed to the core values of our company and look forward to working closely with our exceptional team to accelerate innovation at this critical phase. Though global healthcare has always focused on the problem of emerging infections, the last 18 months have demonstrated that companies like NDD, who strive to not only be proactive but also reactive, are crucial to help build a better, more patient-oriented world.”
